Genentech

Genentech retention plan to cost US$371 million, according to filing

pharmiweb.co.uk     2 hrs ago   35 related          

By The Associated Press SOUTH SAN FRANCISCO, Calif. - A Genentech employee retention plan announced along with its rejection of Roche's buyout offer will cost the biotechnology giant about US$371 million, according to documents...                    

comments

                   

Investment: The drugs don't work

independent.co.uk     5 hrs ago          

The best biotech companies should offer huge rewards to both investors and to society. By Alistair Dawber Friday, 22 August 2008 Investors with shares in Protherics, the UK biotech group that specialises in cancer and critical...                    

comments

Roche Spins NJ Exit As Recruiters Eye Genentech

orglex.com     8 hrs ago          

Never mind that Roche plans to move much of its US pharma operations from Nutley, New Jersey, to South San Francisco, if it succeeds in winning Genentech. Roche execs were happy this week to host New Jersey Governor Jon...                    

comments

                   

Health care mutual funds could help cure what ails you

usatoday.com     3 hrs ago          

You've got the shivers and the shakes. But a dose of health care stocks might help ease your pains. S&P's health care index suffered right along with the S&P 500 until the end of June. "In March, health care stocks were...                    

comments

DNA analysis heralds a health care revolution (at Fortune)

yahoo.com     6 hrs ago          

Did you see the news this week that the two major personal DNA analysis companies, 23andMe and Navigenics, got licensed in California? What a brouhaha its beenregulators issuing cease-and-desist letters, apparently aiming to...                    

comments

                   
yahoo.com: Ohad Hammer yahoo.com

Micromet: Another Seal of Approval (at Seeking Alpha)

yahoo.com     21 hrs ago   6 related          

by: Ohad Hammer posted on: August 21, 2008 | about stocks: MITI There is always a debate regarding market efficiency and to what extent stock prices represent the available information about a company. The article contained...                    

comments

The US FDA to Present at IBC's Global Follow-On Biologics Conference

marketwire.com     15 hrs ago          

WESTBOROUGH, MA--(Marketwire - August 21, 2008) - IBC announced the dates for its upcoming Global Follow-On Biologics Conference. The conference will be held on November 17-18, 2008 at the Hyatt Regency in Bethesda, MD. The...                    

comments

Achillion Appoints Nicholas Simon to Board of Directors

primenewswire.com     yesterday   2 related          

NEW HAVEN, Conn., Aug. 20, 2008 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today...                    

comments

                   

General Dynamics Bucks a Trend -- In Style! (at Motley Fool)

yahoo.com     yesterday   76 related          

The dollar's weakness appears to have spurred a wave of opportunistic bids for U.S. companies by foreign buyers. Take InBev’s $52 billion acquisition of Anheuser-Busch (NYSE: BUD), for example, or Swiss pharmaceutical Roche,...                    

comments

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

tmcnet.com     yesterday   14 related          

710M for Elotuzumab After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. The deal calls for New...                    

comments

1 2 3 4 5 next »